Analytical Technology Transfer in the Pharma Industry

In the pharmaceutical industry, analytical technology transfer (ATT) is a crucial process that involves moving validated analytical methods from one laboratory to another. This is typically done between different locations within the same company or between different companies. The transfer ensures that the recipient laboratory can perform the analytical method reliably and consistently, producing results that are comparable to those obtained by the transferring laboratory.

Importance of ATT

The primary aim of analytical technology transfer is to verify that the receiving lab not only understands and can implement the method but also generates accurate and reliable results. This process is vital for maintaining the integrity of drug development and manufacturing and ensuring that quality control is consistent across different sites.

Regulatory Guidelines

Different regulatory agencies have outlined expectations for ATT. For example, USP 1224, ‘transfer of analytical procedures’, includes detailed instructions that address how to carry out the transfer, how to train personnel at the receiving site, and how to verify that the transferred analytical method performs as expected. Several types of transfers are considered: comparative testing, co-validation between two or more laboratories, revalidation, and even transfer waiver.

Despite the existence of these guidelines, there is often room for interpretation, which can lead to variations in how ATT is executed.

Steps in ATT

A typical analytical technology transfer includes:

  • Preparing a detailed transfer protocol.
  • Sharing scientific documentation related to the method, including detailed analytical procedures.
  • Providing reference samples.
  • Executing the required study(ies) at the receiving site to validate the transfer.
  • Assessing the results to confirm that the method performs adequately in the new setting.

Challenges and Considerations

Despite its routine nature, ATT can be complex and challenging. Differences in equipment, reagents, personnel, and even environmental conditions between sites can affect the outcome of the transfer. Therefore, a risk analysis is often performed as part of the transfer protocol to identify and mitigate potential issues.

Analytical technology transfer is a key activity in the pharmaceutical industry that supports the safe and effective production of medications. While it is governed by regulatory expectations, the specific practices can vary, requiring careful planning and execution to ensure success.

About the author

Tamar Oved
QA & CMC Director @ ADRES

Tamar is QA and CMC director at ADRES. She has over sixsteen years of experience in the pharmaceutical and biotechnology industry. She is experienced in quality assurance, quality control and manufacturing of drugs, biological products and medical devices. She oversees GMP, GLP and CMC activities at production or testing sites. Tamar also has a vast experience with aseptic processes and with CMC and quality requirements during clinical stages of products development.

Linkedin
Go back to the Magazine

Subscribe Now to the Bio-Startup Standard

Notify me for the next issue!

    Drug Licensing Vs. Apartment Rental

    The Virtual-Tangible Fine Line

    Drafting a technology license agreement is a complex professional matter, typically handled by lawyers specializing exclusively in the field. Surprisingly, the principles and rules of an apartment rental agreement, a topic familiar to many, can assist in navigating and understanding the concepts of IP licensing.

    Below, we will review the overlapping points between these two agreements – different yet surprisingly similar – which will greatly facilitate our ability to recognize and navigate technology licensing agreements.

    In the example before us, we will talk about licensing a patent for drug manufacturing versus renting an apartment.

    Let’s start with the agreement terms that define and limit the subject of the transaction and the scope of the license or the rental:

    1. The subject of the rental – an apartment– is registered in the Land Registry in the name of the owner/lessor, indicating ownership of the entire apartment without the ability to split ownership of specific rooms. Similarly, The subject of the license – a patent is registered in the Patent Office in the name of its owner/licensor, denoting ownership of the entire patent without the ability to split it.

    2. The rental period – Example: 5 years with an option for extension. The license period – Example: For the duration of the patent’s validity, or, for a fixed period with an option for extension.

    3. The permitted use of the apartment – Example: For residential purposes only. The permitted use of the patent – Example: For producing a topical drug only but not for producing an ingestion drug.

    4. Subleasing—Example: The tenant is allowed to sublease. Sub-licensing—Example: The licensee is allowed to grant a sub-license.

    5. The scope of use of the apartment – Example: Renting the living and bedrooms, except for the storage room. The scope of use of the patent – Example: A license limited to part of the technology covered by the patent or some of the patent claims.

    6. Regulatory compliance – Example: The tenant undertakes to comply with all laws applicable to a resident, and the licensee undertakes to comply with the relevant regulations for the exploitation of the patent, the production of the drug, its marketing, etc.

    While acknowledging the great similarity between the aforementioned types of transactions, it is also possible at this stage to discern the advantages and greater flexibility in technology (intellectual property) licensing transactions over the rental of a physical asset.

    For example, while a physical asset’s rental is limited to a defined tenant(s), an intellectual asset can be licensed to multiple users/licensees or a single user/licensee if the license is defined as exclusive. Moreover, in technology licensing, it is possible to stipulate that the license is granted and limited to exploitation in a particular country/territory, while in another country/territory, the license will be granted to another licensee. Furthermore, it is also possible to determine many commercial segmentations – such as: one licensee will obtain a license for production only, while another licensee will be granted a license – for the same patent – for marketing and distribution only.

    For the sake of ‘the sacred balance,’ let us note that renting an apartment (and physical assets in general) has its own advantages: In case of a breach of the rental contract terms, the lessor can take physical steps to restore the asset to its possession, for example, by eviction, replacing the locks, taking actual possession, fencing, etc. In contrast, due to the virtual nature of intellectual property licensing, there is no possibility to literally ‘lay hands’ on the intellectual asset in a situation where the licensee violates the license terms. Complex legal enforcement actions must be taken to prevent the exploitation of the license by the violator.

    Now, let’s go back and compare yet another aspect of the above transactions – so different in nature yet so similar in the framework of their terms – this time, we’ll address certain aspects of the Transactions Consideration:

    1.1 Apartment Rental Consideration—Example: The rent is calculated based on the property’s space. Patent licensing Consideration—Example: Royalties are calculated as a percentage of revenues derived by the licensee from the exploitation of the license.

    1.2 A greater similarity can often be seen in the rental of commercial property (for example, a store in a mall), where it is customary for the consideration paid by the tenant to be partly composed of royalties on the store’s revenues in addition to lump-sum payments made in advance, or during the rental period. Similarly, in licensing, it is customary that, in addition to royalties, the licensee will make lump-sum payments that are not dependent on the revenues derived from exploiting the license. These fixed payments are usually paid both as a one-time payment upon the license coming into effect as well as periodic payments that are not income-dependent.

    2. We have referred above to subleasing versus sublicensing. Indeed, in the context of the consideration, there is much similarity: In subleasing, the primary tenant will pay the lessor all or part of the sublease rent she received from the subtenant. Similarly, in sublicensing, the primary licensee will pay the licensor the agreed portion of the sublicense royalties derived from the sublicensee.

    In summary, the great similarity, which does not always receive due attention, between transactions in tangible assets and transactions in virtual assets demonstrates the ‘tangibility’ of intellectual assets and the ‘virtuality’ aspects in transactions of tangible assets. Realizing and understanding said similarity could meaningfully facilitate the structuring and execution of Tech transfer transactions.

    About the authors

    Adv. Hadar Solomon
    @Pearl Cohen Zedek Latzer Baratz

    Partner, Head of China Desk, Pearl Cohen Hadar Solomon is a highly skilled Israeli Hi-Tech, Corporate, Intellectual-Property and Technology-Transfer Attorney. Prior to joining Pearl Cohen Hadar served on the managements of Lumenis and ESC Medical Systems. He also heads Pearl Cohen’s China desk.

    Profile
    Adv. Hili Rashkovan
    @Pearl Cohen Zedek Latzer Baratz

    Partner, Chair of the IL Technology Transactions Practice Group, Pearl Cohen With over 20 years of experience, Hili focuses on representing companies in licensing and technology transactions, including patent licensing, joint ventures, development, manufacturing, and distribution agreements. Hili has been involved and led securing legal engagements in a huge range of industries including pharma, medical devices, food tech, clean energy, and more.

    Profile
    Go back to the Magazine

    Subscribe Now to the Bio-Startup Standard

    Notify me for the next issue!

      The Crucial Role of Strict Adherence to aseptic processing in Pharmaceutical Manufacturing

      In the highly regulated pharmaceutical and biotech industries, the quality and safety of products are paramount. Particularly in the production of injectable drugs, strict adherence to aseptic operations is not just best practice—it’s a necessity. Operators in these facilities are tasked with the vital role of ensuring that every phase of the manufacturing process is executed flawlessly to prevent contamination and ensure patient safety. This article highlights the essential practices that operators must follow and outlines the potential risks of non-compliance.

      Following Strict Hygiene Practices

      Hygiene is the cornerstone of preventing contamination in pharmaceutical manufacturing. Operators are required to engage in stringent hygiene practices, including:

      • Thorough handwashing: Ensuring hands are meticulously cleaned reduces the risk of introducing microbial contaminants.
      • Wearing sterile clothing: Sterile gowns, gloves, and masks must be worn at all times to create a barrier against potential contaminants.
      • Frequent disinfection of gloves and changing them when contamination risks are detected helps maintain a sterile environment.

      Failure to adhere to these hygiene practices can lead to microbial contamination, which may compromise the safety and effectiveness of the pharmaceutical products.

      Maintaining a Clean Work Environment

      A clean and organized work environment is crucial for minimizing the introduction of contaminants. Operators must ensure:

      • No accumulation of substances, such as drips during pipetting, which can become a source of contamination.
      • Workspaces like Laminar Air Flow (LAF) stations are not overcrowded, as cramped conditions can hinder proper aseptic techniques.

      Ignoring these guidelines can lead to environmental contamination, putting entire production batches at risk.

      Handling Materials Properly

      Proper handling of materials and equipment is essential to maintain aseptic conditions:

      • Using sterilized tools and ensuring that all raw materials are stored appropriately prevents the introduction of contaminants into the manufacturing process.
      • Careful handling of sensitive materials avoids accidental exposure to potential contaminants.

      Mistakes in material handling can result in contamination, leading to significant losses in both time and resources, and in severe cases, product recall.

      Executing Procedures with Precision

      Operators are expected to follow standard operating procedures (SOPs) with precision:

      • Accurate execution of each step in the manufacturing process ensures consistency and quality.
      • Regular monitoring of equipment for cleanliness and functionality helps identify and address potential issues before they affect the product.

      Deviations from SOPs can cause inconsistencies in product quality and may lead to regulatory violations.

      Reporting Anomalies

      Prompt reporting of any deviations from standard procedures or unexpected observations is critical:

      • This allows for immediate corrective actions and helps maintain the integrity of the manufacturing process.
      • Operate without adequate training: Operators should never perform tasks without the necessary training, as this increases the risk of errors.

      Not reporting issues can result in unnoticed contaminations, affecting entire batches and potentially harming patients.

      Prioritizing Safety

      Safety must always be a priority:

      • Operators must adhere to all safety protocols, wear appropriate protective gear, and correctly use equipment.
      • Ignoring safety precautions not only endangers the operator but can also lead to accidents and contamination incidents.

      Failure to maintain safety standards can lead to injuries and compromises in the plant’s aseptic operations, resulting in downtime and financial loss.

      Training and Continuous Improvement

      Operators who feel they need to improve their understanding of these critical aspects can benefit from specialized training courses. These courses provide hands-on experience and step-by-step guidance on crucial practices, such as gowning, material handling, and procedural execution, which are fundamental to maintaining aseptic conditions in pharmaceutical manufacturing.

      For those interested in enhancing their skills in quality assurance in healthcare and pharmaceutical projects, more information can be found at https://adres.bio/lp-scinai-course/

      Operators who feel they need to improve their understanding of these critical aspects can benefit from pharma regulatory consulting. EMA and FDA regulatory consulting can guide you in all relevant requirements and provide training. Contact us for more information.

      Your gateway to mastering aseptic operations: An exclusive hands-on course for pharmaceutical and biotech professionals.

      Master the critical aspects of aseptic operations, with theory and practical sessions led by pharma industry experts in Scinai’s state-of-the-art facility.

      This course is led by Scinai and ADRES and includes lectures by Ministry of Health officials.

      If you have any questions or need further assistance, please feel free to reach out to us at https://adres.bio/contact-us.

      Go back to the Blog
      Skip to content